Document Detail


Development of eye drops containing antihypertensive drugs: formulation of aqueous irbesartan/γCD eye drops.
MedLine Citation:
PMID:  24754413     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Aqueous nanoparticulated eye drop formulations based on γ-cyclodextrin (γCD) complexes were developed and tested in vitro. Three antihypertensive drugs, i.e. enalapril maleate, irbesartan and verapamil HCl, that have been shown to possess IOP-lowering activity were selected for this study. All three drugs displayed Bs-type phase-solubility diagrams in aqueous γCD solutions and had relatively low affinity for γCD. Irbesartan was selected for further formulation development. The drug was relatively stable at pH 4.5 but somewhat less stable at physiologic pH. However, presence of γCD in the aqueous media enhanced the chemical stability of irbesartan. Aqueous γCD-based eye drop formulations containing 1% and 2% (w/v) irbesartan were prepared and the effect of pH on the particles size distribution and drug release investigated. Only ∼2% of the drug was in solution in the pH 4.5 formulations but up to 45% in the pH 7 formulations. The pH 7 formulations, where larger fraction of the drug was in solution, displayed somewhat greater drug permeation flux but much lower drug permeation coefficients than the pH 4.5 formulations. Dynamic light scattering studies indicated the faster permeation was due to formation of smaller particles in presence tyloxapol.
Authors:
Phatsawee Jansook; Chutimon Muankaew; Einar Stefánsson; Thorsteinn Loftsson
Related Documents :
3780113 - Effects of ischaemic heart disease, crohn's disease and antimicrobial therapy on the ph...
7050183 - Pharmacokinetic considerations in the haemodialysis of drugs.
10774263 - Cefuroxime utilization evaluation: impact of physician education on prescribing patterns.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2014-4-23
Journal Detail:
Title:  Pharmaceutical development and technology     Volume:  -     ISSN:  1097-9867     ISO Abbreviation:  Pharm Dev Technol     Publication Date:  2014 Apr 
Date Detail:
Created Date:  2014-4-23     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9610932     Medline TA:  Pharm Dev Technol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Design and evaluation of novel barrier layer technologies for controlling venlafaxine hydrochloride ...
Next Document:  Assessment of left ventricular diastolic function by radionuclide ventriculography in patients with ...